1. PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. PARP Inhibitors Overview

5. Olaparib vs Placebo, BRCA1/2 PSROC SOLO2/ENGOT-OV21

6. SOLO2/ENGOT-OV21 Results

7. Niraparib in HRD+ Advanced OC After Response To Pt-Based Chemotherapy ENGOT-OV16/NOVA, Phase 3

8. ENGOT-OV16/NOVA Results

9. ENGOT-OV16/NOVA PFS by BRCA Status

10. SOLO2 and NOVA Trials Study Design

11. SOLO2 and NOVA Trials AEs

12. Rucaparib in gBRCAmut and sBRCAmut ARIEL2, Phase 2

13. ARIEL2 Efficacy

14. ARIEL2 TEAE in ≥ 20%

15. Resistance to PARP Inhibitors

16. Promoter Hypermethylation

17. Long-Term Exposure to Olaparib BRCAmut and BRCAwt

18. Future Directions

19. Carboplatin/Paclitaxel ± Veliparib Newly Diagnosed Advanced OC

20. Key Takeaways

21. Abbreviations

22. Abbreviations (cont)

23. Abbreviations (cont)